# Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

> **NCT01199133** · PHASE3 · TERMINATED · sponsor: **Stallergenes Greer** · enrollment: 471 (actual)

## Conditions studied

- Allergic Rhinitis Due to Dust Mite

## Interventions

- **DRUG:** 300 IR house dust mites allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT01199133
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-09
- **Target enrollment:** 471 (ACTUAL)
- **Why stopped:** Study population was insufficiently symptomatic to enable evaluation of the efficacy of the treatment. No safety concern.
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199133, "Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01199133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*